Palmitoyl Tetrapeptide-7

Mechanism

An anti-inflammatory skin peptide that calms UV-induced irritation and aging. It works by suppressing the inflammatory signals (IL-6) that skin cells release after sun exposure. Best known as half of the Matrixyl 3000 duo (combined with Palmitoyl Tripeptide-1). Reduces chronic low-grade skin inflammation that drives visible aging.

Effects

## Integumentary System — Anti-Inflammatory/Anti-Immunosenescence [Tier 2 — Moderate Human Data] Palmitoyl-Tetrapeptide-7 (Pal-GQPR) is a lipopeptide that modulates the immune-mediated inflammatory response in skin. It inhibits IL-6 secretion from keratinocytes and macrophages, reducing the chronic low-grade inflammation ("inflammaging") that accelerates skin aging. IL-6 is a key driver of MMP expression — by reducing IL-6, Pal-Tetrapeptide-7 indirectly preserves collagen and elastin from inflammatory degradation. In clinical studies, it reduced UV-induced IL-6 secretion by 28-35% and improved the appearance of photo-damaged skin over 8-12 weeks. ## Immune System — Local Immunomodulation [Tier 3 — In Vitro Data] Beyond IL-6, Pal-Tetrapeptide-7 modulates the activity of Langerhans cells (skin-resident dendritic cells) and reduces excessive complement activation in skin. This rebalances the local immune environment from a pro-inflammatory state (characteristic of aged, photo-damaged skin) toward a more quiescent state without immunosuppression.

Practitioner Guide

## Practical Formulation Guide ### Key Role: The Anti-Inflammatory Half of Matrixyl 3000 Pal-Tetrapeptide-7 is one of the two peptides in Matrixyl 3000 (the other being Pal-Tripeptide-1/Pal-GHK). Matrixyl 3000 is specifically designed as a synergistic combination: Pal-GHK stimulates collagen production while Pal-Tetrapeptide-7 reduces the inflammation that degrades it. ### Effective Concentrations - **As part of Matrixyl 3000:** Use at the manufacturer's recommended level (typically 3-8% of commercial solution). - **As standalone ingredient:** 50-200 ppm active peptide in finished formulation. ### Formulation Considerations - **pH:** Stable at pH 5.0-7.0. - **Compatibility:** Compatible with all major cosmetic peptides. Specifically designed to pair with Pal-Tripeptide-1. - **Best applications:** Anti-aging formulations for photo-damaged skin. Formulations for redness-prone or sensitive skin. Post-procedure recovery products. Products targeting "inflammaging." - **Synergies:** Pairs exceptionally well with niacinamide (also reduces IL-6 and improves barrier function) and ceramides (barrier repair reduces inflammatory trigger exposure). ### Application Protocol - Apply in serum or moisturizer, twice daily. - Particularly valuable in AM formulations where UV-induced inflammation will occur during the day. - Layer under SPF for best anti-inflammaging effect. ### Realistic Expectations - **4 weeks:** Mild reduction in skin redness and reactivity. May notice fewer "bad skin days." - **8 weeks:** Measurable reduction in UV-induced erythema response. Skin appears calmer and more even-toned. - **12+ weeks:** The anti-inflammatory protection translates to preserved collagen over time — this is a long-game ingredient. The benefit accumulates rather than being immediately visible.

Evidence

• Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream.

  Yang F et al. (2024) — Skin Research and Technology — PMID: 38932444

  A 12-week randomized topical eye-cream trial using a multi-component formula that included palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 reported improved hydration, elasticity, collagen-related markers, and wrinkle-related assessments; evidence is supportive but not peptide-isolated.

  moderate

Research Summary

## Tier 1 — Strong Clinical Evidence - None independently (it is a cosmeceutical, not a drug). However, as a component of Matrixyl 3000, it is included in numerous clinical studies. ## Tier 2 — Moderate Evidence - Clinical studies (Sederma) demonstrating 28-35% reduction in UV-induced IL-6 secretion and improved photo-damage appearance over 8-12 weeks - Well-characterized mechanism: IL-6 inhibition → reduced MMP expression → collagen preservation - Synergistic efficacy with Pal-Tripeptide-1 (Matrixyl 3000 combination) validated in comparative studies ## Tier 3 — Preclinical/Theoretical - In vitro data on Langerhans cell modulation and complement inhibition - Potential application in inflammatory skin conditions (rosacea, atopic dermatitis) — not studied clinically - Long-term immunological effects of chronic IL-6 suppression in skin not formally evaluated